Dr. Shiran Zimri, Head of Scientific Programs at NeuroSense Therapeutics
Israeli crypto service startup CryptoHub hit a $30 million valuation with a $6 million raise, including $3 million from Tectona, led by Chairman Yariv Gilat and CEO Yossi Barnea. At the same time, NeuroSense Therapeutics, an Israeli medtech firm, completed enrollment in PARADIGM, a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS). And Cision, an Israeli startup offering an end-to-end consumer and media intelligence and communications platform, renewed its partnership with Elon Musk’s Twitter.
Founded in 2021 by Eliran Ouzan and Shlomi Bazel, CryptoHub offers a variety of what it boasts are high-quality, one-of-kind crypto trading tools and innovations to “improve the average crypto trader’s experience and safety when trading crypto.” At CryptoHub, traders can utilize a range of resources, including a tool that performs sophisticated data analysis of every token on the blockchain, a smart contract builder, and launchpads.
Cision is a consumer and media intelligence and communications platform enabling public relations, marketing and communications professionals around the world to understand, influence and amplify their stories. Cision enables the next generation of leaders to strategically operate in the modern media landscape where company success is directly impacted by public opinion.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“Our technology, deep expertise, and holistic global omni-media investment strategy, put us in the unique position to transform media data into the actionable insights our clients must have to effectively understand, shape and amplify their stories and strategies in real time. Our decade long-standing partnership with Twitter helps us deliver on this commitment,” said Pehr Luedtke, Senior Vice President Content Partnerships at Cision.
In addition to Twitter, Cision initiated other unique partnerships this year. In January, Cision’s Brandwatch division became an official partner of Reddit and was first to market with Reddit’s full data firehose. In March, Cision’s PR Newswire division partnered with Captivate, a leading out-of-home video network, giving press release clients greater visibility through Captivate’s 14,500 screens in premium locations across the US and Canada.
Founded by CEO Micha Breakstone and CTO Edmund Benami as well as scientific co-founder Gil Shklarski, NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.
NeuroSense says as a novel combination therapy of two FDA approved drugs, celecoxib and ciprofloxacin, with well-established safety profiles, PrimeC is designed to synergistically target several key ALS mechanisms that contribute to motor neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation to potentially inhibit the progression of ALS.
“PARADIGM is tracking 17 different outcome measures while the primary endpoint remains focused on biomarkers. This wealth of outcome data will not only be used to optimize the design of a future pivotal Phase 3 study for PrimeC, but we believe it will provide greater insight into the mechanisms of ALS for the scientific community as we advance toward a day when ALS will become a highly treatable disease,” stated NeuroSense’s Chief Medical Officer, Dr. Ferenc Tracik.
“We are pleased to share this milestone for the PARADIGM clinical trial,” stated NeuroSense’s CEO, Alon Ben-Noon. “We are grateful to the participants living with ALS, their families, and the study investigators for their commitment to the PARADIGM trial and for taking part in our mission to develop an effective therapy for ALS.”
